The nucleic acid drug developer previously secured $18m in a series A round backed by contract research company SNBL in February 2015.
Wave Life Sciences, a US-based biotechnology developer backed by contract research company SNBL, closed a $66m series B round yesterday led by growth capital firm Foresite Capital.
The oversubscribed round also featured Fidelity Management and Research, New Leaf Venture Partners, Redmile Group, Jennison Associates, Cormorant Asset Management, Clough Capital Partners, RA Capital Management and Kagoshima Shinsangyo Sosei Investment.
Founded in 2014, Wave is working on a drug discovery platform that will fuel the development of nucleic acid-based treatments for rare…
